乳腺癌中的HER2受体：病理生理学、临床应用及治疗新进展
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.
作者信息
Mitri Zahi, Constantine Tina, O'Regan Ruth
机构信息
Department of Internal Medicine, Emory University, Atlanta, GA 30322, USA.
出版信息
Chemother Res Pract. 2012;2012:743193. doi: 10.1155/2012/743193. Epub 2012 Dec 20.
Abstract
Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20-30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. The effectiveness of Trastuzumab has been well validated in research as well as in clinical practice. The addition of Trastuzumab to standard of care chemotherapy in clinical trials has been shown to improve outcomes for early stage as well as metastatic HER2 positive breast cancer. The most clinically significant side effect of Trastuzumab is the risk of cardiac myocyte injury, leading to the development of congestive heart failure. The emergence of patterns of resistance to Trastuzumab has led to the discovery of new monoclonal antibodies and other targeted agents aimed at overcoming Trastuzumab resistance and improving survival in patients diagnosed with HER2 positive breast cancers.
摘要
人表皮生长因子受体2（HER2）在约20%-30%的乳腺癌肿瘤中过度表达。它与侵袭性更强的疾病、更高的复发率和死亡率增加相关。曲妥珠单抗是一种HER2受体阻滞剂，已成为HER2阳性乳腺癌治疗的标准疗法。曲妥珠单抗的有效性在研究和临床实践中均得到了充分验证。在临床试验中，将曲妥珠单抗添加到标准化疗中已被证明可改善早期和转移性HER2阳性乳腺癌的治疗效果。曲妥珠单抗最具临床意义的副作用是心肌细胞损伤的风险，会导致充血性心力衰竭。对曲妥珠单抗耐药模式的出现促使人们发现了新的单克隆抗体和其他靶向药物，旨在克服曲妥珠单抗耐药性并提高HER2阳性乳腺癌患者的生存率。
相似文献
1
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.乳腺癌中的HER2受体：病理生理学、临床应用及治疗新进展
Chemother Res Pract. 2012;2012:743193. doi: 10.1155/2012/743193. Epub 2012 Dec 20.
2
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.针对 HER2 靶向治疗耐药的策略演进：针对 PI3K/Akt/mTOR 通路。
Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015.
3
A systematic review of dual targeting in HER2-positive breast cancer.HER2 阳性乳腺癌的双重靶向治疗系统评价。
Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11.
4
Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.帕妥珠单抗：一种用于治疗 HER2 阳性转移性乳腺癌的新型靶向治疗药物。
Pharmacotherapy. 2014 Jan;34(1):60-71. doi: 10.1002/phar.1338. Epub 2013 Aug 5.
5
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.曲妥珠单抗治疗 HER2 阳性转移性乳腺癌之外的新兴方法。
Ann Oncol. 2013 Oct;24(10):2492-2500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4.
6
Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.曲妥珠单抗：其在HER2阳性转移性和早期乳腺癌治疗中的应用综述
Drugs. 2006;66(4):449-75. doi: 10.2165/00003495-200666040-00005.
7
The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.曲妥珠单抗在早期乳腺癌中的作用：当前数据及治疗建议。
Curr Treat Options Oncol. 2007 Feb;8(1):47-60. doi: 10.1007/s11864-007-0008-2.
8
Lapatinib.拉帕替尼
Recent Results Cancer Res. 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2.
9
Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.曲妥珠单抗在HER2阳性转移性和早期乳腺癌治疗中的聚焦
BioDrugs. 2006;20(4):259-62. doi: 10.2165/00063030-200620040-00007.
10
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.人表皮生长因子受体2阳性转移性乳腺癌患者的当前治疗方法
Front Oncol. 2018 Apr 3;8:89. doi: 10.3389/fonc.2018.00089. eCollection 2018.
引用本文的文献
1
Luminescent Properties and Cytotoxic Activity of 2-phenylbenzoxazole Fluorosulfate Derivatives.2-苯基苯并恶唑氟硫酸盐衍生物的发光性质及细胞毒性活性
Int J Mol Sci. 2025 Jul 27;26(15):7261. doi: 10.3390/ijms26157261.
2
Correlation between CTMP expression levels and resistance to trastuzumab in HER2 + metastatic breast cancer.CTMP表达水平与HER2阳性转移性乳腺癌对曲妥珠单抗耐药性之间的相关性
Discov Oncol. 2025 Jul 16;16(1):1342. doi: 10.1007/s12672-025-03210-x.
3
KDM3A Modulates Trastuzumab Resistance in HER2- Positive Breast Cancer Cells via the PI3K/AKT/ERK Pathway.KDM3A通过PI3K/AKT/ERK途径调节HER2阳性乳腺癌细胞中的曲妥珠单抗耐药性。
Biochem Genet. 2025 Jul 2. doi: 10.1007/s10528-025-11170-8.
4
Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.小分子酪氨酸激酶抑制剂在HER2阳性乳腺癌新辅助治疗中的疗效与安全性：一项系统评价和网状Meta分析
BMC Cancer. 2025 Jul 1;25(1):1072. doi: 10.1186/s12885-025-14404-5.
5
Clinical significance of HER2 overexpression in biliary tract carcinoma --a meta analysis.HER2过表达在胆管癌中的临床意义——一项荟萃分析
Front Oncol. 2025 May 14;15:1534005. doi: 10.3389/fonc.2025.1534005. eCollection 2025.
6
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine.免疫组织化学评估的HER2状态对接受曲妥珠单抗 emtansine治疗的转移性乳腺癌患者治疗反应的影响
Medicina (Kaunas). 2025 Apr 29;61(5):819. doi: 10.3390/medicina61050819.
7
Characterization of soil-derived Bacillus subtilis metabolites against breast cancer: In vitro and in silico studies.土壤来源的枯草芽孢杆菌代谢产物对乳腺癌的特性研究：体外和计算机模拟研究
Saudi Pharm J. 2025 Apr 17;33(1-2):3. doi: 10.1007/s44446-025-00006-6.
8
Expression of HER2 in urothelial carcinoma and its significance.HER2在尿路上皮癌中的表达及其意义。
Curr Urol. 2025 May;19(3):201-207. doi: 10.1097/CU9.0000000000000249. Epub 2024 May 27.
9
In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with Ac.用锕标记的抗HER2抗体偶联物的体外和体内评估
EJNMMI Radiopharm Chem. 2025 Apr 4;10(1):16. doi: 10.1186/s41181-025-00337-8.
10
Cannabinoids as Promising Inhibitors of HER2-Tyrosine Kinase: A Novel Strategy for Targeting HER2-Positive Ovarian Cancer.大麻素作为HER2酪氨酸激酶的潜在抑制剂：一种靶向HER2阳性卵巢癌的新策略。
ACS Omega. 2025 Feb 8;10(6):6191-6200. doi: 10.1021/acsomega.4c11108. eCollection 2025 Feb 18.
本文引用的文献
1
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.帕妥珠单抗联合曲妥珠单抗加多西他赛治疗转移性乳腺癌。
N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
2
Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.曲妥珠单抗诱导的心脏功能障碍：“双重打击”。
Exp Clin Cardiol. 2011 Fall;16(3):70-4.
3
Adjuvant trastuzumab in HER2-positive breast cancer.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌。
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
4
Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI.多学科方法在心血管肿瘤学研究试验（MANTICORE 101--乳腺）中新型疗法的原理和设计：一项随机、安慰剂对照试验，旨在使用心脏 MRI 确定常规心力衰竭药物治疗是否可以预防 HER2+早期乳腺癌患者曲妥珠单抗介导的左心室重构。
BMC Cancer. 2011 Jul 27;11:318. doi: 10.1186/1471-2407-11-318.
5
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.曲妥珠单抗联合辅助化疗治疗可手术的人表皮生长因子受体 2 阳性乳腺癌的 4 年随访：NCCTG N9831 和 NSABP B-31 数据的联合分析。
J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.
6
Immune effects of trastuzumab.曲妥珠单抗的免疫效应。
J Cancer. 2011;2:317-23. doi: 10.7150/jca.2.317. Epub 2011 May 25.
7
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.随机 II 期研究比较了曲妥珠单抗联合多西他赛与曲妥珠单抗序贯治疗后进展时单独使用多西他赛作为 HER2+转移性乳腺癌一线化疗的疗效和安全性：HERTAX 试验。
Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11.
8
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.曲妥珠单抗辅助化疗后治疗 1 年用于人表皮生长因子受体 2 阳性早期乳腺癌患者：一项随机对照试验的 4 年随访。
Lancet Oncol. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. Epub 2011 Feb 25.
9
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.III 期随机研究比较多西他赛联合曲妥珠单抗与长春瑞滨联合曲妥珠单抗作为人表皮生长因子受体 2 阳性转移性或局部晚期乳腺癌的一线治疗：HERNATA 研究。
J Clin Oncol. 2011 Jan 20;29(3):264-71. doi: 10.1200/JCO.2010.30.8213. Epub 2010 Dec 13.
10
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.CLEOPATRA：帕妥珠单抗联合曲妥珠单抗治疗人表皮生长因子受体 2 阳性转移性乳腺癌的 III 期评估。
Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065.
Zotero 插件